Opioid Use Disorder

1. Clinical Overview

Summary

Opioid use disorder (OUD) is a chronic, relapsing brain disease characterized by compulsive opioid use despite harmful consequences. [1,2] It encompasses a spectrum from prescription opioid misuse to heroin dependence, representing one of the most significant public health crises globally. The disorder involves neurobiological adaptations in reward circuitry, physical dependence with severe withdrawal syndrome, and life-threatening complications including fatal overdose. [3,4]

The opioid epidemic has evolved through three distinct waves: prescription opioid overprescribing (1990s-2000s), heroin resurgence (2010s), and synthetic opioid proliferation particularly fentanyl (2015-present). [5] Understanding the pharmacological basis of tolerance, dependence, and addiction is critical for effective management.

Key Facts

Clinical Pearls

• Pinpoint pupils (miosis): Pathognomonic for opioid intoxication; persist even in profound hypoxia (vs other causes of coma)
• Naloxone administration: Community distribution programmes reduce overdose mortality by 30-40% [10]
• Fentanyl crisis: 50-100× more potent than morphine; responsible for 70% of US opioid deaths [5]
• Post-release vulnerability: Overdose risk increased 40-fold in first 2 weeks after prison release [11]
• Concurrent sedatives: Combined opioid-benzodiazepine use increases overdose risk 5-10-fold [12]
• Pregnancy: Opioid maintenance therapy safer than withdrawal; prevents neonatal complications [13]
• BBV screening: Essential in IV drug users - HCV prevalence 40-80%, HIV 5-15% in high-risk populations [14]

---

2. Epidemiology

Global and Regional Burden

Exam Detail: The Three Waves of the Opioid Epidemic (US-centric but globally relevant):

1. First Wave (1990s-2000s): Prescription opioid overprescribing following aggressive pain management campaigns; OxyContin introduction 1996
2. Second Wave (2010-2015): Heroin resurgence as prescription crackdowns shifted users to cheaper heroin
3. Third Wave (2015-present): Illicitly manufactured fentanyl contamination of heroin/counterfeit pills

Risk Factors

---

3. Aetiology and Pathophysiology

Opioid Receptor Neuropharmacology

Opioids exert effects through binding to G-protein coupled receptors (GPCRs) distributed throughout the central and peripheral nervous systems. [3,4]

Exam Detail: Molecular Mechanism of μ-Opioid Receptor (MOR) Activation:

1. Binding: Opioid agonist binds to extracellular domain of MOR
2. G-protein activation: Conformational change activates Gi/Go proteins
3. Downstream effects:
   • Inhibition of adenylyl cyclase → ↓ cAMP → ↓ PKA activity
   • Opening of K+ channels → hyperpolarization → ↓ neuronal excitability
   • Closing of voltage-gated Ca2+ channels → ↓ neurotransmitter release
4. Net effect: Neuronal inhibition in pain pathways (analgesia) and reward circuits (euphoria)

Respiratory Depression Mechanism:

• MOR activation in medullary respiratory centers (pre-Bötzinger complex)
• ↓ Responsiveness to hypercapnia (CO₂)
• ↓ Respiratory drive → hypoventilation → hypoxia → respiratory arrest

The Neurobiology of Addiction: Reward Circuitry

Opioid Administration
         ↓
MOR Activation in Ventral Tegmental Area (VTA)
         ↓
Disinhibition of Dopaminergic Neurons
         ↓
↑↑ Dopamine Release in Nucleus Accumbens (NAc)
         ↓
Reinforcement of Drug-Seeking Behavior
         ↓
Neuroplastic Changes (ΔFosB accumulation)
         ↓
ADDICTION: Compulsive use despite harm

Key Neurobiological Adaptations [3,4]:

1. Reward Sensitization: Repeated opioid exposure → enhanced dopamine response → positive reinforcement
2. Stress/Dysphoria System Activation: Upregulation of corticotropin-releasing factor (CRF) in amygdala → negative affect in withdrawal
3. Prefrontal Cortex Dysfunction: Impaired executive control → compulsive use despite consequences
4. Conditioned Responses: Environmental cues trigger craving via glutamatergic pathways

Tolerance, Dependence, and Withdrawal

Exam Detail: Withdrawal Pathophysiology - The Locus Coeruleus (LC) Hypothesis:

During chronic opioid use:

• MOR activation in LC → inhibition of noradrenergic neurons → clinical effects (sedation, miosis)
• Compensatory upregulation of adenylyl cyclase (AC) and cAMP production
• ↑ Expression of CREB (cAMP response element-binding protein)

Upon opioid cessation:

• Rebound hyperactivity of LC due to loss of opioid inhibition + upregulated AC/cAMP
• Massive noradrenaline surge → sympathetic overdrive
• Clinical manifestations: mydriasis, lacrimation, rhinorrhoea, sweating, tachycardia, hypertension, diarrhoea, piloerection

This explains why α₂-agonists (lofexidine, clonidine) are effective for withdrawal - they suppress LC noradrenergic hyperactivity.

Overdose Pathophysiology

Critical Triad: Miosis + Respiratory Depression + Decreased Consciousness [4]

Fentanyl-Specific Considerations [5]:

• Potency: 50-100× morphine (depending on analogue)
• Rapid onset: IV fentanyl peaks in 3-5 minutes
• Chest wall rigidity: Unique to high-dose fentanyl; "wooden chest syndrome" impairs ventilation
• Naloxone resistance: May require higher/repeated doses due to high receptor affinity

---

4. Clinical Presentation

DSM-5 Diagnostic Criteria for Opioid Use Disorder

≥2 criteria within 12 months (paraphrased):

1. Larger amounts or longer periods than intended
2. Persistent desire or unsuccessful efforts to cut down
3. Great deal of time obtaining, using, or recovering
4. Craving or strong desire to use
5. Failure to fulfill major role obligations
6. Continued use despite social/interpersonal problems
7. Important activities given up or reduced
8. Recurrent use in hazardous situations
9. Continued use despite physical/psychological problems
10. Tolerance (need for increased amounts or diminished effect)
11. Withdrawal (characteristic syndrome or opioids taken to relieve withdrawal)

Severity: Mild (2-3 criteria), Moderate (4-5), Severe (≥6)

Clinical Presentations

A. Acute Opioid Intoxication

Red Flag Features Indicating Severe Intoxication/Overdose:

• Respiratory rate less than 8/min
• SpO₂ less than 90% on room air
• GCS less than 8 (requires airway protection)
• Cyanosis (profound hypoxia)
• Apnea (respiratory arrest)

B. Opioid Overdose

Diagnosis is clinical: Classic triad + circumstantial evidence

Differential Diagnosis of Pinpoint Pupils:

• Opioid overdose (most common)
• Pontine hemorrhage (usually other focal neurology)
• Organophosphate poisoning (fasciculations, salivation, bronchospasm)
• Cholinergic medications (pilocarpine)

C. Opioid Withdrawal Syndrome

NOT life-threatening (unlike alcohol/benzodiazepine withdrawal) but extremely distressing. [7]

Clinical Withdrawal Scales:

• Clinical Opioid Withdrawal Scale (COWS): 11-item scale (score 0-48); less than 12 mild, 13-24 moderate, 25-36 moderately severe, > 36 severe
• Subjective Opioid Withdrawal Scale (SOWS): Patient self-rated 16-item scale

Exam Detail: Why is opioid withdrawal not fatal (vs alcohol/benzodiazepine)?

• Alcohol/benzodiazepine withdrawal: GABA-A receptor downregulation → sudden cessation → unopposed glutamate excitotoxicity → seizures, delirium tremens, autonomic instability → death
• Opioid withdrawal: Noradrenergic hyperactivity in locus coeruleus → sympathetic surge → distressing but no seizures or life-threatening complications in otherwise healthy individuals
• Exception: Severe dehydration from vomiting/diarrhea (especially in vulnerable populations: elderly, infants) can be dangerous

Neonatal Abstinence Syndrome (NAS): CAN be life-threatening in newborns; requires specialized treatment

D. Chronic Opioid Use - Signs and Sequelae

---

5. Investigations

Acute Overdose Investigations

Important Note: Diagnosis and treatment are clinical - do NOT delay naloxone while awaiting drug screen results.

Assessment of Opioid Use Disorder (Outpatient/Clinic Setting)

Exam Detail: Why is fentanyl often NOT detected on standard immunoassay urine drug screens?

• Standard "opiate" immunoassays detect morphine and codeine metabolites
• Fentanyl has a different chemical structure (phenylpiperidine vs phenanthrene)
• Specific fentanyl immunoassay or GC-MS/LC-MS required for detection
• Clinical implication: Negative UDS does not exclude fentanyl overdose

---

6. Management

A. Acute Opioid Overdose - Emergency Management

Time-critical intervention: Opioid overdose is reversible with appropriate treatment. [10]

Initial Assessment and Resuscitation

Approach patient → Assess responsiveness (AVPU/GCS)
        ↓
    AIRWAY
- Head tilt, chin lift
- Recovery position if breathing
- Suction if secretions
- Consider airway adjuncts (OP/NP airway)
- If GCS less than 8: intubation may be required
        ↓
    BREATHING
- Assess: Look, Listen, Feel
- RR, SpO₂, chest movement
- High-flow oxygen (15L/min via non-rebreather mask)
- Bag-valve-mask ventilation if apneic/inadequate
        ↓
    CIRCULATION
- IV/IO access
- Blood glucose (exclude hypoglycemia)
- Monitor: BP, HR, ECG
        ↓
    NALOXONE ADMINISTRATION

Naloxone Dosing

Naloxone: Pure μ-opioid receptor antagonist; reverses ALL opioid effects. [10]

Key Principles:

1. Titrate to respiratory effort (RR > 10-12/min, adequate tidal volume), NOT full alertness
2. Repeat dosing: Naloxone half-life 30-90 min; opioid effects (especially methadone, fentanyl) last longer → re-sedation common
3. Observation period: Minimum 1-2 hours (short-acting opioids), 6-12 hours (long-acting opioids, fentanyl)
4. Naloxone infusion: If repeated boluses required: 60% of initial effective dose per hour IV

Clinical Pearl: Precipitated Withdrawal from Naloxone:

• Naloxone immediately reverses opioid receptor activation → acute withdrawal in dependent individuals
• Symptoms: Agitation, sweating, tachycardia, hypertension, vomiting, diarrhea, myalgias
• Management: Reassurance, supportive care; withdrawal is unpleasant but not life-threatening
• Patient may leave against medical advice → explain re-sedation risk; offer harm reduction advice

Fentanyl-Specific Challenges:

• High-dose fentanyl may require multiple naloxone doses (2-10 mg total) or continuous infusion
• "Wooden chest syndrome" (chest wall rigidity) may require muscle relaxation + mechanical ventilation

Post-Resuscitation Care

---

B. Opioid Withdrawal Management

Principle: Withdrawal is not life-threatening but extremely distressing; treatment aims to minimize suffering and engage with long-term treatment. [7]

Withdrawal Management Approaches

Inpatient vs Outpatient Withdrawal:

• Outpatient: Motivated patient, stable social support, mild-moderate dependence
• Inpatient: Severe dependence, polysubstance use, failed outpatient attempts, pregnancy, medical/psychiatric comorbidity

Exam Detail: Why can buprenorphine precipitate withdrawal?

• Buprenorphine is a partial agonist with very high receptor affinity
• When given to someone with full agonist (heroin, methadone) on board:
  • Buprenorphine displaces the full agonist from μ-receptors
  • But provides less intrinsic activity (partial agonism)
  • "Net effect: Sudden ↓ in receptor activation → precipitated withdrawal"
• Solution: Delay buprenorphine until patient in mild-moderate withdrawal (COWS > 8-12)

---

C. Long-Term Treatment of Opioid Use Disorder

Gold Standard: Opioid Agonist Therapy (OAT) - reduces mortality by 50%, reduces crime, improves quality of life. [7,8,9]

Pharmacological Treatments

1. Methadone Maintenance Therapy (MMT)

2. Buprenorphine (± Naloxone)

3. Extended-Release Naltrexone (Vivitrol)

Comparison of Opioid Agonist Therapies

Psychosocial Interventions

Pharmacotherapy + psychosocial support > pharmacotherapy alone. [7]

---

D. Harm Reduction Strategies

Principle: Reduce harms associated with drug use without requiring abstinence. [10]

Clinical Pearl: The Evidence for Harm Reduction:

• Cochrane Review: NSPs reduce HIV transmission by 50% (RR 0.52) [14]
• Meta-analysis: THN programmes associated with 30% reduction in overdose deaths [10]
• Vancouver Insite Study: SDCR associated with 35% reduction in overdose deaths within 500m radius; no increase in drug use or crime
• Harm reduction is cost-effective: Every £1 spent on NSPs saves £15 in HIV treatment costs

Harm reduction is evidence-based medicine and should be offered alongside (not instead of) treatment.

---

E. Special Populations

Pregnancy and Opioid Use Disorder

Chronic Pain and Opioid Use Disorder

Adolescents and Young Adults

• Rising incidence in 15-25 age group (prescription opioids → heroin trajectory)
• Buprenorphine effective in adolescents (age ≥16); emerging evidence for ages 13-15
• Family involvement critical
• Address co-occurring mental health disorders (depression, trauma, ADHD)

---

7. Complications

Medical Complications

Psychiatric Complications

Social Complications

• Homelessness: 10-20× higher prevalence
• Incarceration: 15% of UK prisoners have OUD [11]
• Unemployment: Chaotic lifestyle, stigma
• Relationship breakdown: Family estrangement
• Stigma: Healthcare, employment, social exclusion

---

8. Prognosis and Outcomes

Predictors of Good Outcome:

• Retention in OAT (single strongest predictor)
• Adequate dosing (methadone ≥60 mg/day)
• Psychosocial support
• Stable housing
• Treatment of co-occurring mental health disorders
• Abstinence from other substances (especially benzodiazepines, alcohol)

Predictors of Poor Outcome:

• Polysubstance use (especially benzodiazepines) [12]
• Homelessness
• Severe psychiatric comorbidity
• Repeated treatment dropout
• Ongoing injection drug use

---

9. Prevention and Public Health

---

10. Guidelines and Evidence

Key Clinical Guidelines

Landmark Studies

1. Mattick RP et al. Cochrane Database Syst Rev 2009: Methadone maintenance therapy vs no opioid replacement - RR 0.36 for mortality [9]
2. Lee JD et al. NEJM 2018: Extended-release naltrexone vs buprenorphine - buprenorphine superior for retention (relapse prevention trial)
3. Sordo L et al. BMJ 2017: Mortality risk during and after OAT - 50% reduction during treatment; 8-fold increased risk post-cessation [9]
4. Jones HE et al. NEJM 2010: MOTHER study - buprenorphine vs methadone in pregnancy - both effective; buprenorphine → less severe NAS [13]
5. McDonald R & Strang J. Lancet 2016: Take-home naloxone meta-analysis - 30% reduction in overdose deaths [10]
6. Platt L et al. Lancet 2017: Needle and syringe programmes for HCV prevention - 50% reduction in HCV acquisition [14]
7. Hedegaard H et al. NCHS Data Brief 2021: Drug Overdose Deaths in US - Fentanyl involved in 70% of opioid deaths [5]

---

11. Examination Focus (MRCPsych / MRCP)

Viva Questions and Model Answers

Exam Detail: Q1: A 32-year-old man presents to the emergency department unresponsive with pinpoint pupils and a respiratory rate of 6/min. How would you manage this patient?

Model Answer:

"This patient has the classic triad of opioid overdose: decreased consciousness, pinpoint pupils, and respiratory depression, which is life-threatening.

Immediate management follows ABC:

• Airway: Head tilt, chin lift, recovery position if breathing; consider airway adjuncts
• Breathing: High-flow oxygen 15L/min; bag-valve-mask ventilation if inadequate respiratory effort
• Circulation: IV/IO access; monitor BP, HR, ECG
• Point-of-care glucose to exclude hypoglycemia

Antidote: Naloxone - I would give 100-200 micrograms IV initially, titrating to restore respiratory effort (not full consciousness, to avoid precipitated withdrawal). If no IV access, 400 micrograms IM. Repeat every 2-3 minutes up to 2 mg total if inadequate response.

Monitoring: Naloxone half-life is shorter than most opioids, so re-sedation is common. I'd observe for at least 1-2 hours for short-acting opioids like heroin, and 6-12 hours for long-acting opioids or fentanyl.

Post-resuscitation: ABG (to assess hypoxia/hypercapnia), ECG, supportive care. This is a critical window to engage with addiction services - I'd offer take-home naloxone, harm reduction advice, and referral to addiction specialist for opioid agonist therapy.

Investigations: FBC, LFTs, BBV screen (Hep B, C, HIV if IV drug use)."

---

Q2: Compare and contrast methadone and buprenorphine for opioid agonist therapy.

Model Answer:

"Both are evidence-based treatments that reduce mortality by approximately 50% compared to no treatment.

Methadone:

• Mechanism: Full μ-opioid receptor agonist
• Pharmacokinetics: Long half-life 24-36 hours; oral administration; once-daily dosing
• Dosing: Start 10-30 mg, increase gradually; maintenance 60-120 mg (optimal dose for most patients)
• Administration: Requires daily supervised consumption initially at specialist clinics
• Advantages: Slightly better retention in treatment (60-70% at 1 year); strong evidence base
• Disadvantages: QTc prolongation (requires ECG monitoring); overdose risk especially during induction; less flexible (daily attendance); stigma
• Monitoring: Baseline and annual ECG; if QTc > 500ms, consider dose reduction or switch

Buprenorphine:

• Mechanism: Partial μ-agonist and κ-antagonist
• Pharmacokinetics: Very long half-life 24-72 hours; sublingual administration; usually combined with naloxone (Suboxone) to deter IV misuse
• Dosing: Must delay until patient in mild withdrawal (COWS > 8-12) to avoid precipitated withdrawal; start 2-4 mg, increase to 12-24 mg maintenance
• Administration: Take-home dosing possible earlier; can be prescribed in primary care (UK)
• Advantages: Safer - ceiling effect on respiratory depression; no QTc prolongation; greater flexibility; effective analgesic
• Disadvantages: Risk of precipitated withdrawal if given too early; slightly lower retention vs methadone (though high-dose buprenorphine comparable)

Choice depends on: Patient preference, polysubstance use, QTc risk factors, need for flexibility, and local service availability. Both are effective; the best medication is the one the patient will take."

---

Q3: Explain the pathophysiology of opioid withdrawal and why it is not life-threatening, unlike alcohol withdrawal.

Model Answer:

"Opioid withdrawal results from neuroadaptive changes during chronic opioid use, particularly in the locus coeruleus (LC) in the pons, which is the main noradrenergic nucleus in the brain.

During chronic opioid use:

• μ-opioid receptor activation in the LC inhibits noradrenergic neurons
• Compensatory upregulation of adenylyl cyclase and cAMP occurs
• Increased expression of CREB transcription factor

Upon opioid cessation:

• Loss of opioid inhibition + upregulated cAMP pathway → rebound hyperactivity of LC
• Massive noradrenaline surge → sympathetic overdrive

Clinical manifestations:

• Autonomic: Sweating, tachycardia, hypertension, piloerection ('cold turkey'), mydriasis (dilated pupils)
• GI: Nausea, vomiting, diarrhea, abdominal cramps
• Musculoskeletal: Myalgias, arthralgias, bone pain
• Psychological: Anxiety, insomnia, dysphoria, craving

Why NOT life-threatening?

• Opioid withdrawal causes sympathetic hyperactivity but no seizures and no delirium
• The noradrenergic surge is very unpleasant but does not cause life-threatening complications in otherwise healthy individuals
• Exception: Severe dehydration from vomiting/diarrhea can be dangerous in vulnerable populations (elderly, neonates)

Contrast with alcohol/benzodiazepine withdrawal:

• These involve GABA-A receptor downregulation during chronic use
• Sudden cessation → unopposed glutamate excitotoxicity
• Results in seizures, delirium tremens, autonomic instability → potentially fatal
• This is why alcohol/benzodiazepine withdrawal requires medical detoxification, whereas opioid withdrawal can be managed symptomatically

Treatment: α₂-agonists like lofexidine or clonidine suppress LC hyperactivity, reducing withdrawal symptoms. Alternatively, opioid substitution therapy (methadone/buprenorphine) prevents withdrawal entirely."

OSCE Station: Breaking Bad News - Discussing Opioid Agonist Therapy

Scenario: 28-year-old man with heroin use disorder, post-overdose (naloxone administered). Discuss treatment options.

Key Points to Cover:

1. Empathy and non-judgmental approach ("Opioid use disorder is a medical condition, not a moral failing")
2. Explain overdose risk and harm reduction (take-home naloxone, never use alone, avoid mixing with sedatives)
3. Offer opioid agonist therapy as gold standard: "Treatment with methadone or buprenorphine reduces the risk of death by half"
4. Explain OAT: "A prescribed medication that prevents withdrawal and cravings, allowing you to stabilize your life"
5. Address misconceptions: "This is not 'replacing one drug with another' - it's evidence-based treatment, like insulin for diabetes"
6. Psychosocial support: counseling, housing, employment support
7. BBV screening and vaccination
8. Safety netting: "If you're not ready for treatment today, we'll be here when you are. Here's a naloxone kit and information about local services."

---

12. Patient / Layperson Explanation

What is Opioid Use Disorder?

Opioid use disorder (OUD) is a medical condition where your brain becomes dependent on opioids - drugs like heroin, morphine, oxycodone, or fentanyl. It's not about willpower or moral weakness; it's a brain disease that changes how your reward system works, making it extremely difficult to stop using even when you want to.

What Happens in Overdose?

Opioids slow down your breathing. In an overdose, breathing can become so slow that it stops completely, cutting off oxygen to your brain and heart. This is fatal within minutes if not treated.

Warning signs of overdose:

• Pinpoint pupils (very small pupils, like a dot)
• Very slow or no breathing
• Blue lips or fingernails
• Unresponsive or unconscious

If you suspect overdose: Call 999 immediately, give naloxone if available, perform rescue breathing, stay with the person.

What is Naloxone?

Naloxone (Narcan) is a medication that reverses opioid overdose within 2-3 minutes. It's safe, can't be misused, and has no effect if opioids aren't present. It's available free through community programmes and pharmacies in the UK.

How to use:

• Intranasal spray: 1 spray in each nostril
• Injection: 1 injection into outer thigh muscle (like an EpiPen)
• Can repeat after 3 minutes if no response
• Always call 999 - naloxone wears off and the person may stop breathing again

What is Withdrawal?

When you stop using opioids after regular use, your body goes into withdrawal. It feels like severe flu: sweating, chills, muscle aches, stomach cramps, diarrhea, anxiety, and intense cravings. It's extremely unpleasant but not life-threatening (unlike alcohol withdrawal).

Withdrawal peaks at 1-3 days and improves over 5-10 days, but cravings and sleep problems can last weeks to months.

What Treatments Are Available?

1. Opioid Agonist Therapy (OAT) - The most effective treatment:

• Methadone or buprenorphine (Suboxone): Prescribed medications that prevent withdrawal and cravings without causing a "high"
• Taken once daily under supervision initially, then you can take home once stable
• Reduces risk of death by 50% - this is life-saving treatment
• Not "replacing one drug with another"
• it's medical treatment, like insulin for diabetes or inhalers for asthma
• You can stay on OAT for months, years, or life - whatever works for you

2. Counseling and Support:

• Regular meetings with an addiction counselor
• Help with housing, benefits, employment
• Treatment for depression, anxiety, trauma
• Support groups (Narcotics Anonymous, SMART Recovery)

3. Harm Reduction (if not ready for treatment):

• Naloxone kit: Reverse overdose - get one free from your local service
• Clean needles: Needle exchange programmes prevent infections
• Never use alone: Someone can call 999 and give naloxone if you overdose
• Start small: Especially if you've been in prison, hospital, or off opioids - your tolerance is low, and your usual dose could kill you
• Avoid mixing: Opioids + benzodiazepines or alcohol = very high overdose risk
• Test your drugs: Fentanyl test strips can detect contamination (available in some areas)

What About Pregnancy?

If you're pregnant and using opioids:

• Do NOT try to detox - withdrawal can harm your baby
• Opioid agonist therapy (methadone or buprenorphine) is safe and recommended during pregnancy
• Your baby will need monitoring after birth for neonatal abstinence syndrome (baby withdrawal), but this is treatable
• You can breastfeed on OAT - it's encouraged and helps reduce withdrawal symptoms in your baby

Can I Recover?

Yes. Recovery is possible.

Opioid use disorder is a chronic condition, like diabetes or asthma. Some people recover completely, others manage it long-term with treatment. Relapses are common - they're part of the process, not a failure.

Recovery looks different for everyone:

• Some people stay on OAT long-term and live full, healthy lives
• Others taper off medication after years of stability
• What matters is what works for you: reduced drug use, better health, stable housing, reconnecting with family

You don't have to do this alone. Treatment works. Help is available.

Where to Get Help (UK)

• Emergency (overdose): Call 999
• GP: Ask for referral to local drug and alcohol service
• Self-referral: Most areas accept self-referrals to addiction services
• Naloxone: Ask your GP, pharmacy, or local drug service for a free naloxone kit + training
• Helplines:
  • "Frank: 0300 123 6600 (drugs information and advice)"
  • "Narcotics Anonymous: 0300 999 1212"
  • "Samaritans: 116 123 (24/7 emotional support)"

---

13. References

1. UNODC. World Drug Report 2022. United Nations Office on Drugs and Crime. doi:10.18356/9789210058216

2. Volkow ND, Koob GF, McLellan AT. Neurobiologic Advances from the Brain Disease Model of Addiction. N Engl J Med. 2016;374(4):363-371. doi:10.1056/NEJMra1511480

3. Kosten TR, George TP. The Neurobiology of Opioid Dependence: Implications for Treatment. Sci Pract Perspect. 2002;1(1):13-20. doi:10.1151/spp021113

4. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician. 2008;11(2 Suppl):S105-120.

5. Hedegaard H, Miniño AM, Spencer MR, Warner M. Drug Overdose Deaths in the United States, 1999-2020. NCHS Data Brief. 2021;(428):1-8.

6. Office for National Statistics (ONS). Deaths related to drug poisoning in England and Wales: 2022 registrations. Statistical Bulletin. 2023.

7. NICE Guideline NG215. Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults. National Institute for Health and Care Excellence. 2022.

8. Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev. 2003;(3):CD002208. doi:10.1002/14651858.CD002208

9. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. doi:10.1136/bmj.j1550

10. McDonald R, Strang J. Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction. 2016;111(7):1177-1187. doi:10.1111/add.13326

11. Binswanger IA, Stern MF, Deyo RA, et al. Release from prison--a high risk of death for former inmates. N Engl J Med. 2007;356(2):157-165. doi:10.1056/NEJMsa064115

12. Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 2012;125(1-2):8-18. doi:10.1016/j.drugalcdep.2012.07.004

13. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320-2331. doi:10.1056/NEJMoa1005359

14. Platt L, Minozzi S, Reed J, et al. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. Addiction. 2018;113(3):545-563. doi:10.1111/add.14012

15. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Drug Report 2023: Trends and Developments. Publications Office of the European Union, Luxembourg. 2023.

16. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. MMWR Recomm Rep. 2022;71(3):1-95. doi:10.15585/mmwr.rr7103a1

17. American Society of Addiction Medicine (ASAM). The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. J Addict Med. 2020;14(2S Suppl 1):1-91. doi:10.1097/ADM.0000000000000633

18. World Health Organization (WHO). Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: World Health Organization; 2009.